Drug Trial Radar · NCT04592315
A Study to Assess the Safety, Tolerability and Pharmacokinetics of Lipovirtide in HIV-infected Patients
Last checked: Nov 20, 2026Latest source record: May 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
46
Actual
Start
Jan 23, 2021
Primary completion
May 2, 2023
Study completion Jul 11, 2023
Sponsor
- Lead sponsor
- Shanxi Kangbao Biological Product Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Institute of Pathogen Biology, Beijing, China
- First posted
- Oct 19, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To evaluate the safety, tolerability of single dose lipovirtide injection in HIV-infected individuals without prior antiviral treatment, and to investigate the pharmacokinetic characteristics of infected patients.
Conditions
- HIV Infections
Interventions
Lipovirtide InjectionDrug
Single dosage of Lipovirtide Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Treatment-Related Adverse Events as Assessed by DAIDS v1.0Time frame: Day 1 to Day 15
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing You'an Hospital, Beijing Medical University
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.